Pfizer (PFE) is trading lower premarket on Tuesday after mixed Q4 results and an FY23 outlook which is seen lower than expected. Q4 Adjusted EPS grew +44% Y/Y to $1.14, beating ...

Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per ...

Pfizer's Q4 2023 financial report: adjusted EPS beats estimates at $0.10, FY2023 EPS down 72%, Q4 sales decline 41% to $14.25B. CEO's positive outlook and reaffirmed 2024 guidance.

Pfizer spun off the Upjohn business in November and merged it with Mylan to form Viatris. All of the company's Q4 numbers excluded any impact from Upjohn, which was accounted for as a discontinued ...

Pfizer (PFE) is scheduled to announce Q4 earnings results on Tuesday, January 31st, before market open.The consensus EPS Estimate is $1.04 (-3.7% Y/Y) and the consensus Revenue Estimate ...

Pfizer (NYSE: PFE) is scheduled to report its Q4 2022 results on Tuesday, January 31, and we expect it to see little movement, with its revenue falling slightly ahead, but earnings likely missing ...

After a tornado damaged one of the largest sterile injectable drug manufacturing facilities in the world, Pfizer predicted the Rocky Mount, N.C., plant will be producing again in the next few ...

However, Pfizer easily beat what Wall Street analysts expected on the bottom line. The company announced Q4 adjusted diluted earnings per share (EPS) of $0.62, a 32% year-over-year jump.

Analysts estimate adjusted EPS of $0.85 vs. $0.42 in Q4 FY 2020. Pfizer's revenue is expected to grow at a robust pace, but slower than Q3 FY 2021. The U.S. government has doubled its order for ...

In short, Pfizer's future is going to look very different from -- and much better than -- its recent past. Its Q4 results don't matter much with that future in view. 10 stocks we like better than ...